NCT05141721: An ongoing trial by Seattle Project Corporation
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05141721 |
|---|---|
| Title | A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 12, 2022 |
| Completion date | March 31, 2027 |
| Required reporting date | March 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |